White label ELPA - ClinicalTrials.eu

Study of Elacestrant and Ribociclib for Patients with Endocrine-Responsive HER2-Negative Early Breast Cancer

Not recruiting

2 1 1 1
Investigated Drugs:
Study of PRT3789 and Pembrolizumab for Patients with Advanced Solid Tumors, Esophageal Cancer, or NSCLC with SMARCA4 Mutation

Not recruiting

2 1 1 1
Investigated Drugs:
- PRT3789
- Pembrolizumab
Study on the Effectiveness and Safety of Lunsekimig (SAR443765) for Adults with Moderate to Severe Atopic Dermatitis

Not recruiting

2 1
Investigated Diseases:
- Dermatitis atopic
Investigated Drugs:
- LUNSEKIMIG
Study on the Effect of Survodutide on Heart Safety in Patients with Obesity and Cardiovascular or Kidney Disease

Not recruiting

3 1
Investigated Drugs:
- BI 456906
- SURVODUTIDE
+11
Long-term safety study of zagociguat tablets in patients with MELAS syndrome (Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) who completed previous trial

Not recruiting

2 1 1
Investigated Diseases:
- MELAS syndrome
Investigated Drugs:
- Zagociguat
Study of Retatrutide for Patients with Obesity, Overweight, and Chronic Low Back Pain

Not recruiting

3 1 1
Investigated Diseases:
Investigated Drugs:
- Ly3437943 Sodium
Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Atopic Dermatitis

Not recruiting

2 1
Investigated Drugs:
- Ro7790121
Study for Adults with Chronic Myeloid Leukemia Using Asciminib Alone or with Nilotinib

Not recruiting

2 1 1 1
Investigated Drugs:
- Nilotinib
- Asciminib Hydrochloride
Study on How Cagrilintide and Semaglutide Help People with Overweight or Obesity Reduce Weight

Not recruiting

3 1
Investigated Diseases:
- Obesity
+4
Study on the Safety and Effects of PF-07868489 in Patients with Pulmonary Arterial Hypertension

Not recruiting

1 1
Investigated Diseases:
- Pulmonary arterial hypertension
Investigated Drugs:
- PF-07868489
+1

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies